The cells were treated with or without 1 μg/ml
Jagged-1 (R&D Systems, Minneapolis, MN, USA) for 72 h in the presence of
anti-CD3/CD28 beads at a bead-to-cell ratio of 1:1 (Invitrogen, Carlsbad, CA, USA), 20 ng/ml
IL-6, 10 ng/ml
TGF-β, 20 ng/ml
IL-23 (PeproTech, Rocky Hill, NJ, USA), 10 μg/ml
anti-IFN-γ and 10 μg/ml
anti-IL-4 (eBioscience, San Diego, CA, USA). The additional cells were treated with the equal volume of phosphate buffered saline (PBS) as a control. Six hours before the end of the treatment, the cells were stimulated with 50 ng/ml
phorbol-12-myristate-13-acetate (PMA) (Sigma-Aldrich, St. Louis, MO, USA) plus 1 μg/ml of ionomycin (Alexis, Lausen, Switzerland) for the below experiments. Meanwhile, 10 μg/ml of
GolgiStop (Becton Dickinson, Franklin Lakes, NJ, USA) was added to the cells. The cells were washed with PBS and stained with FITC-conjugated anti-mouse CD4 (0.125 μg per million cells) at 37°C for 20 min. The cells were washed, fixed, permeabilized with Fixation/Permeabilization Buffer and intracellular-stained with
PE-conjugated anti-mouse IL-17 (0.05 μg per million cells) and
FITC-conjugated anti-mouse IFN-γ (0.25 μg per million cells) (eBioscience, San Diego, CA, USA) for 30 min at 4°C, and analyzed with a flow cytometer (
FACSCalibur, Becton Dickinson, Mountain View, CA, USA).
Wang Y., Xing F., Ye S., Xiao J., Di J., Zeng S, & Liu J. (2015). Jagged-1 signaling suppresses the IL-6 and TGF-β treatment-induced Th17 cell differentiation via the reduction of RORγt/IL-17A/IL-17F/IL-23a/IL-12rb1. Scientific Reports, 5, 8234.